Literature DB >> 8581561

Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly.

S S Zhan1, R Veerhuis, W Kamphorst, P Eikelenboom.   

Abstract

Recent studies have shown that cerebral beta amyloid (A beta) protein deposition is a necessary, but not sufficient, factor to develop the pathology of Alzheimer's disease (AD). In the present immunohistochemical study, we have investigated in AD the distribution of A beta associated proteins in the cerebral neocortex, in the cerebellar cortex where A beta plaques are mainly of the diffuse type, and also in the cerebral neocortex of non-demented patients with A beta plaques. Results show that immunolabeling for C1q, C4c, C3d, alpha 1-ACT and Apolipoprotein E (ApoE) occurs in the great majority of A beta plaques in all groups. ApoJ is present in A beta plaques of the cerebral neocortex in AD and in non-demented elderly, but is almost absent from those of the AD cerebellar cortex. C4Bp and P-component, in contrast to AD, rarely occurs in A beta plaques of the cerebral neocortex in the non-demented elderly. Heparan sulphate proteoglycan (HSPG) core protein and intercellular adhesion molecule-1 (ICAM-1) are absent in the diffuse A beta plaques in the AD cerebellum. These differences in distribution and expression of A beta associated proteins may be determined by brain region specific factors (cerebral cortex versus cerebellar cortex) and clinical state (demented versus non-demented cases). We suggest that, besides A beta peptide, certain A beta associated proteins are required for both amyloid plaque formation and for the induction of neurofibrillary changes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581561     DOI: 10.1016/1055-8330(95)90018-7

Source DB:  PubMed          Journal:  Neurodegeneration        ISSN: 1055-8330


  15 in total

Review 1.  Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Hyoung-gon Lee; George Perry; Xiongwei Zhu; Rudy J Castellani; Mark A Smith
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Authors:  F L Van Muiswinkel; P Eikelenboom
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

4.  An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.

Authors:  Pavitra Kannan; Martin Schain; Warren W Kretzschmar; Lora Weidner; Nicholas Mitsios; Balázs Gulyás; Hans Blom; Michael M Gottesman; Robert B Innis; Matthew D Hall; Jan Mulder
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

5.  The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and down syndrome.

Authors:  C A Lemere; T J Grenfell; D J Selkoe
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

6.  Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice.

Authors:  Joo-Yong Lee; Toby B Cole; Richard D Palmiter; Sang Won Suh; Jae-Young Koh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques.

Authors:  Chiara Mencarelli; Gerard H Bode; Mario Losen; Mahesh Kulharia; Peter C Molenaar; Robert Veerhuis; Harry W M Steinbusch; Marc H De Baets; Gerry A F Nicolaes; Pilar Martinez-Martinez
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

Review 8.  The significance of neuroinflammation in understanding Alzheimer's disease.

Authors:  P Eikelenboom; R Veerhuis; W Scheper; A J M Rozemuller; W A van Gool; J J M Hoozemans
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 9.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.